Christiaan V. Widdershoven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christiaan V. Widdershoven has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Patricia Jeannelle Zondervan
Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
3 shared publications - Axel Bex
Department of Urology Royal Free London NHS Foundation Trust London UK
2 shared publications - Brigitte M. Aarts
Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
2 shared publications - Brunolf W. Lagerveld
Department of Urology OLVG Amsterdam The Netherlands
2 shared publications A. Bex
1 shared publicationA. Van Heerik
1 shared publication
Latest Publications
- Open Access
- 15 December 2022
- Published by Elsevier in European Urology Open Science
- Vol. 48, 1-11
A Systematic Review of Heterogeneity in Outcome Definition and Reporting in Localised Renal Cancer
- 15 December 2022
- Published by Elsevier in European Urology Open Science
- Vol. 48, 1-11
Open AccessA Systematic Review of Heterogeneity in Outcome Definition and Reporting in Localised Renal Cancer
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S779
Partial Nephrectomy: Is there substantial overtreatment of patients?
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S779
Partial Nephrectomy: Is there substantial overtreatment of patients?
- Open Access
- 20 June 2020
- Published by Springer Nature in Abdominal Radiology
- Vol. 46 (1) , 373-379
Renal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow-up
Purpose: To assess the difference between renal mass biopsy (RMB) performed either before or during the ablation procedure. Methods: A retrospective multicenter study was performed in patients with a cT1 renal mass treated with ablation between January 2007 and July 2019, including a search in the national pathology database for patients with a RMB planned for ablation. Patient and tumor characteristics and information on malignant, benign, and non-diagnostic biopsy results were collected to establish rates of overtreatment and number of ablations avoided in case of benign or non-diagnostic histology. Results: RMB was performed in 714 patients, of which 231 patients received biopsy before planned ablation, and 483 patients at the time of ablation. Pathology results before ablation were malignant in 63% (145/231), benign in 20% (46/231) and non-diagnostic in 17% (40/231). Pathology results at the time of ablation were malignant in 67.5% (326/483), benign in 16.8% (81/483) and non-diagnostic in 15.7% (76/483), leading to a total of 32.5% of ablation of benign or non-diagnostic lesions. Of the patients with a benign biopsy obtained before ablation, 80.4% (37/46) chose not to undergo ablation. Patients with inconclusive biopsy before planned ablation chose an informed individualized approach including ablation, repeated biopsy, or no intervention in 56%, 34% and 10%. Conclusion: This study emphasizes the importance of obtaining a biopsy prior to the ablation procedure in a separate session to lower the rate of potentially unnecessary ablations.
- 20 June 2020
- Published by Springer Nature in Abdominal Radiology
- Vol. 46 (1) , 373-379
Open AccessRenal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow-up
Purpose: To assess the difference between renal mass biopsy (RMB) performed either before or during the ablation procedure. Methods: A retrospective multicenter study was performed in patients with a cT1 renal mass treated with ablation between January 2007 and July 2019, including a search in the national pathology database for patients with a RMB planned for ablation. Patient and tumor characteristics and information on malignant, benign, and non-diagnostic biopsy results were collected to establish rates of overtreatment and number of ablations avoided in case of benign or non-diagnostic histology. Results: RMB was performed in 714 patients, of which 231 patients received biopsy before planned ablation, and 483 patients at the time of ablation. Pathology results before ablation were malignant in 63% (145/231), benign in 20% (46/231) and non-diagnostic in 17% (40/231). Pathology results at the time of ablation were malignant in 67.5% (326/483), benign in 16.8% (81/483) and non-diagnostic in 15.7% (76/483), leading to a total of 32.5% of ablation of benign or non-diagnostic lesions. Of the patients with a benign biopsy obtained before ablation, 80.4% (37/46) chose not to undergo ablation. Patients with inconclusive biopsy before planned ablation chose an informed individualized approach including ablation, repeated biopsy, or no intervention in 56%, 34% and 10%. Conclusion: This study emphasizes the importance of obtaining a biopsy prior to the ablation procedure in a separate session to lower the rate of potentially unnecessary ablations.
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1230
Pre- or peri-ablative biopsies: A comparison of different diagnostic strategies in small renal masses treated with ablation
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1230
Pre- or peri-ablative biopsies: A comparison of different diagnostic strategies in small renal masses treated with ablation